View ValuationCapsoVision 将来の成長Future 基準チェック /26CapsoVisionは、15.8%と27.2%でそれぞれ年率15.8%で利益と収益が成長すると予測される一方、EPSはgrowで32.7%年率。主要情報15.8%収益成長率32.73%EPS成長率Medical Equipment 収益成長16.2%収益成長率27.2%将来の株主資本利益率n/aアナリストカバレッジLow最終更新日15 May 2026今後の成長に関する最新情報Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 18%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$19.2m to US$15.8m. EPS estimate increased from -US$0.49 to -US$0.48 per share. Medical Equipment industry in the US expected to see average net income growth of 12% next year. Consensus price target reaffirmed at US$10.50. Share price was steady at US$7.44 over the past week.すべての更新を表示Recent updatesNew Risk • May 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$24m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).New Risk • May 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$25m Forecast net loss in 1 year: US$23m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$23m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).お知らせ • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026お知らせ • May 01CapsoVision, Inc., Annual General Meeting, Jun 11, 2026CapsoVision, Inc., Annual General Meeting, Jun 11, 2026.Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 18%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$19.2m to US$15.8m. EPS estimate increased from -US$0.49 to -US$0.48 per share. Medical Equipment industry in the US expected to see average net income growth of 12% next year. Consensus price target reaffirmed at US$10.50. Share price was steady at US$7.44 over the past week.Reported Earnings • Mar 27Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: US$1.03 loss per share. Revenue: US$13.6m (up 15% from FY 2024). Net loss: US$25.3m (loss widened 27% from FY 2024). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.お知らせ • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026新しいナラティブ • Feb 09AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy AdoptionCatalysts About CapsoVision CapsoVision develops wire free, cloud connected capsule endoscopy systems for gastrointestinal disease screening and diagnosis. What are the underlying business or industry changes driving this perspective?新しいナラティブ • Jan 25Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI PlayerCatalysts About CapsoVision CapsoVision develops cloud connected capsule endoscopy systems that use panoramic imaging and AI to support noninvasive gastrointestinal screening and diagnostics. What are the underlying business or industry changes driving this perspective?お知らせ • Jan 01CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®?CapsoVision, Inc. announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®?. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged two years and older. The Company believes that it is a more advanced capsule endoscopy solution compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables.Board Change • Dec 31High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Julia Gouw was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (14% average weekly change).Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.17 loss per share. Net loss: US$7.92m (flat on 3Q 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.お知らせ • Nov 11CapsoVision, Inc. Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening CapsuleCapsoVision, Inc. announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company's CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision's mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma the most common form of pancreatic cancer is among the fatal cancers worldwide, with a five-year survival rate of only 8%, largely because it is diagnosed at advanced stages that cannot be treated. Currently, no early screening tools are recommended to identify the disease at a treatable stage in the general population. Unlike traditional endoscopic or imaging procedures, CapsoCam UGI is completely non-invasive. Patients simply allow a pill-sized camera, eliminating the need for sedation, intubation, or recovery time, while enabling physicians to review detailed images through a secure, cloud-based system. The FDA's Breakthrough Devices Program is designed to expedite the development and review of technologies that may offer more effective diagnosis or treatment for life-threatening conditions where no adequate alternatives exist. If granted, the designation would allow CapsoVision to work closely with the FDA to accelerate development and shape upcoming clinical studies, leading the regulatory review process. Pancreatic cancer remains one of the most lethal malignancies, with a five- year survival rate of only 10%, a figure that has seen little improvement in decades. It is now the third leading cause of cancer-related death in the United States, despite accounting for just over 3% of all cancer cases. Early detection can improve survival more than fourteen-fold5, yet no non-invasive screening method for the general population is currently recommended. This underscores an urgent global need for innovative, patient-friendly diagnostic technologies that can visualize pancreatic abnormalities earlier, before symptoms emerging and while curative treatment is still possible.お知らせ • Nov 04+ 1 more updateCapsovision, Inc. Appoints David Garcia as Senior Vice President of Finance and Principal Accounting Officer, Effective November 3, 2025CapsoVision, Inc. announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Mr. Garcia brings more than 20 years of financial leadership experience spanning corporate finance, capital markets, and strategic transactions. He joins CapsoVision after serving as Vice President of Financial Planning and Analysis at Matterport, Inc., where he helped lead its initial public offering and played a key role in the company's recent acquisition. His background also includes senior finance roles at View, Inc., Intelepeer Cloud Communications, and Align Technology, as well as earlier experience with Oracle and Deloitte. Mr. Garcia earned a Master of Business Administration in Finance from The Wharton School, University of Pennsylvania, and a Bachelor of Arts in Economics from Stanford University. Effective as of November 3, 2025, David Garcia, Senior VP of Finance of CapsoVision, Inc. (the “Company”), has been appointed by the board of directors of the Company (the “Board”) to serve as the Company’s principal financial officer and principal accounting officer. Mr. Garcia, age 51, has more than 20 years of financial leadership experience and most recently served as Vice President of Financial Planning and Analysis at Matterport, Inc. from October 2020 through October 2025.お知らせ • Oct 31CapsoVision, Inc. to Report Q3, 2025 Results on Nov 13, 2025CapsoVision, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025お知らせ • Sep 27CapsoVision, Inc. Announces Board ChangesOn September 22, 2025, Rebecca Petersen notified CapsoVision, Inc. (the Company") of her planned retirement as the Company's Senior Director of Clinical Affairs, effective October 15, 2025. Concurrently, the Company promoted Ms. Keri Jorgenson to Director of Clinical Operations and Ms. Jorgenson, together with the other members of the clinical operations team, will assume responsibility of the Company's clinical development operations and activities. The Company does not anticipate any disruption to its clinical development operations and activities during this transition. Ms. Jorgenson joined CapsoVision in March 2022 and most recently served as the Company's Senior Clinical Project Manager, working closely with Ms. Petersen and the Company's broad, experienced clinical operations team.お知らせ • Sep 04CapsoVision, Inc. Announces Step Down of Kevin Lundquist as Chief Financial Officer, Effective August 27, 2025Effective August 27, 2025, Kevin Lundquist has stepped down as Chief Financial Officer of CapsoVision, Inc. (the “Company”). The Company has begun the search to identify a successor. The Company and Mr. Lundquist have mutually agreed that Mr. Lundquist will be available to provide consulting assistance and transition support to the Company for up to six months, until February 28, 2026. In connection therewith, the Company and Mr. Lundquist will enter into a Consulting Agreement to take effect immediately (the “ Consulting Agreement ”).Reported Earnings • Aug 19Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: US$2.02 loss per share. Net loss: US$4.63m (flat on 2Q 2024). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.お知らせ • Aug 01CapsoVision, Inc. to Report Q2, 2025 Results on Aug 14, 2025CapsoVision, Inc. announced that they will report Q2, 2025 results After-Market on Aug 14, 2025お知らせ • Jul 02CapsoVision, Inc. has completed an IPO in the amount of $27.5 million.CapsoVision, Inc. has completed an IPO in the amount of $27.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,500,000 Price\Range: $5 Discount Per Security: $0.35 Transaction Features: Sponsor Backed OfferingBoard Change • Jun 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman Chen Tsai was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.業績と収益の成長予測NasdaqCM:CV - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202721-20N/A-21112/31/202616-25N/A-2513/31/202614-27-24-24N/A12/31/202514-25-23-23N/A9/30/202513-23-21-21N/A6/30/202513-20-22-22N/A3/31/202512-21-21-21N/A12/31/202412-20-20-20N/A12/31/202310-11-12-11N/Aアナリストによる今後の成長予測収入対貯蓄率: CV今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CV今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: CV今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: CVの収益 ( 27.2% ) US市場 ( 11.7% ) よりも速いペースで成長すると予測されています。高い収益成長: CVの収益 ( 27.2% ) 20%よりも速いペースで成長すると予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: CVの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YHealthcare 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/18 08:41終値2026/05/15 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋CapsoVision, Inc. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Bruce JacksonBenchmark CompanyJason WittesRoth Capital PartnersKyle BauserRoth Capital Partners
Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 18%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$19.2m to US$15.8m. EPS estimate increased from -US$0.49 to -US$0.48 per share. Medical Equipment industry in the US expected to see average net income growth of 12% next year. Consensus price target reaffirmed at US$10.50. Share price was steady at US$7.44 over the past week.
New Risk • May 15New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$24m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$24m free cash flow). Minor Risks Currently unprofitable and not forecast to become profitable next year (US$24m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).
New Risk • May 11New minor risk - ProfitabilityThe company is currently unprofitable and not forecast to become profitable over the next year. Trailing 12-month net loss: US$25m Forecast net loss in 1 year: US$23m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Currently unprofitable and not forecast to become profitable next year (US$23m net loss next year). Share price has been volatile over the past 3 months (14% average weekly change).
お知らせ • May 02CapsoVision, Inc. to Report Q1, 2026 Results on May 14, 2026CapsoVision, Inc. announced that they will report Q1, 2026 results After-Market on May 14, 2026
お知らせ • May 01CapsoVision, Inc., Annual General Meeting, Jun 11, 2026CapsoVision, Inc., Annual General Meeting, Jun 11, 2026.
Major Estimate Revision • Apr 02Consensus revenue estimates decrease by 18%, EPS upgradedThe consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast fell from US$19.2m to US$15.8m. EPS estimate increased from -US$0.49 to -US$0.48 per share. Medical Equipment industry in the US expected to see average net income growth of 12% next year. Consensus price target reaffirmed at US$10.50. Share price was steady at US$7.44 over the past week.
Reported Earnings • Mar 27Full year 2025 earnings: EPS in line with expectations, revenues disappointFull year 2025 results: US$1.03 loss per share. Revenue: US$13.6m (up 15% from FY 2024). Net loss: US$25.3m (loss widened 27% from FY 2024). Revenue missed analyst estimates by 2.6%. Earnings per share (EPS) were mostly in line with analyst estimates. Revenue is forecast to grow 46% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US.
お知らせ • Mar 13CapsoVision, Inc. to Report Q4, 2025 Results on Mar 26, 2026CapsoVision, Inc. announced that they will report Q4, 2025 results After-Market on Mar 26, 2026
新しいナラティブ • Feb 09AI Delays And Mounting R&D Costs Will Eventually Reward Capsule Endoscopy AdoptionCatalysts About CapsoVision CapsoVision develops wire free, cloud connected capsule endoscopy systems for gastrointestinal disease screening and diagnosis. What are the underlying business or industry changes driving this perspective?
新しいナラティブ • Jan 25Cloud And AI Capsule Endoscopy Will Reshape Long Term Prospects For This Undervalued GI PlayerCatalysts About CapsoVision CapsoVision develops cloud connected capsule endoscopy systems that use panoramic imaging and AI to support noninvasive gastrointestinal screening and diagnostics. What are the underlying business or industry changes driving this perspective?
お知らせ • Jan 01CapsoVision Announces 510(k) Submission for the Addition of AI-Assisted Reading Module in CapsoCam Plus®?CapsoVision, Inc. announced submission of its 510(k) application to the Food and Drug Administration (FDA) for its proprietary AI-assisted module for CapsoCam Plus®?. The addition of this reading tool will improve the detection of clinically significant pathology, as well as reduce clinician review time. The Company intends for U.S. commercialization activities to commence after the FDA clearance. CapsoVision's CapsoCam Plus capsule endoscopy system is intended for visualization of the small bowel mucosa to detect abnormalities of the small bowel in adults and children aged two years and older. The Company believes that it is a more advanced capsule endoscopy solution compared to competitor systems, both in how it captures and presents images of the GI tract and the clinical workflow and patient experience that it enables.
Board Change • Dec 31High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Director Julia Gouw was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
New Risk • Dec 11New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-US$21m free cash flow). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (14% average weekly change).
Reported Earnings • Nov 14Third quarter 2025 earnings: EPS and revenues miss analyst expectationsThird quarter 2025 results: US$0.17 loss per share. Net loss: US$7.92m (flat on 3Q 2024). Revenue missed analyst estimates by 4.0%. Earnings per share (EPS) also missed analyst estimates by 36%. Revenue is forecast to grow 47% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Medical Equipment industry in the US.
お知らせ • Nov 11CapsoVision, Inc. Submits Breakthrough Device Designation Application to FDA for Pancreatic Cancer Screening CapsuleCapsoVision, Inc. announced that it has submitted an application to the U.S. Food and Drug Administration (FDA) on November 6, 2025 requesting Breakthrough Device Designation (BDD) to accelerate development of the Company's CapsoCam UGI capsule endoscopy system for use in early-stage pancreatic cancer detection. This submission represents an important milestone in CapsoVision's mission to expand its capsule-based diagnostics platform beyond the small bowel and address some of the most challenging diseases in gastroenterology. Pancreatic ductal adenocarcinoma the most common form of pancreatic cancer is among the fatal cancers worldwide, with a five-year survival rate of only 8%, largely because it is diagnosed at advanced stages that cannot be treated. Currently, no early screening tools are recommended to identify the disease at a treatable stage in the general population. Unlike traditional endoscopic or imaging procedures, CapsoCam UGI is completely non-invasive. Patients simply allow a pill-sized camera, eliminating the need for sedation, intubation, or recovery time, while enabling physicians to review detailed images through a secure, cloud-based system. The FDA's Breakthrough Devices Program is designed to expedite the development and review of technologies that may offer more effective diagnosis or treatment for life-threatening conditions where no adequate alternatives exist. If granted, the designation would allow CapsoVision to work closely with the FDA to accelerate development and shape upcoming clinical studies, leading the regulatory review process. Pancreatic cancer remains one of the most lethal malignancies, with a five- year survival rate of only 10%, a figure that has seen little improvement in decades. It is now the third leading cause of cancer-related death in the United States, despite accounting for just over 3% of all cancer cases. Early detection can improve survival more than fourteen-fold5, yet no non-invasive screening method for the general population is currently recommended. This underscores an urgent global need for innovative, patient-friendly diagnostic technologies that can visualize pancreatic abnormalities earlier, before symptoms emerging and while curative treatment is still possible.
お知らせ • Nov 04+ 1 more updateCapsovision, Inc. Appoints David Garcia as Senior Vice President of Finance and Principal Accounting Officer, Effective November 3, 2025CapsoVision, Inc. announced the appointment of David Garcia as Senior Vice President of Finance, effective November 3, 2025. Mr. Garcia brings more than 20 years of financial leadership experience spanning corporate finance, capital markets, and strategic transactions. He joins CapsoVision after serving as Vice President of Financial Planning and Analysis at Matterport, Inc., where he helped lead its initial public offering and played a key role in the company's recent acquisition. His background also includes senior finance roles at View, Inc., Intelepeer Cloud Communications, and Align Technology, as well as earlier experience with Oracle and Deloitte. Mr. Garcia earned a Master of Business Administration in Finance from The Wharton School, University of Pennsylvania, and a Bachelor of Arts in Economics from Stanford University. Effective as of November 3, 2025, David Garcia, Senior VP of Finance of CapsoVision, Inc. (the “Company”), has been appointed by the board of directors of the Company (the “Board”) to serve as the Company’s principal financial officer and principal accounting officer. Mr. Garcia, age 51, has more than 20 years of financial leadership experience and most recently served as Vice President of Financial Planning and Analysis at Matterport, Inc. from October 2020 through October 2025.
お知らせ • Oct 31CapsoVision, Inc. to Report Q3, 2025 Results on Nov 13, 2025CapsoVision, Inc. announced that they will report Q3, 2025 results After-Market on Nov 13, 2025
お知らせ • Sep 27CapsoVision, Inc. Announces Board ChangesOn September 22, 2025, Rebecca Petersen notified CapsoVision, Inc. (the Company") of her planned retirement as the Company's Senior Director of Clinical Affairs, effective October 15, 2025. Concurrently, the Company promoted Ms. Keri Jorgenson to Director of Clinical Operations and Ms. Jorgenson, together with the other members of the clinical operations team, will assume responsibility of the Company's clinical development operations and activities. The Company does not anticipate any disruption to its clinical development operations and activities during this transition. Ms. Jorgenson joined CapsoVision in March 2022 and most recently served as the Company's Senior Clinical Project Manager, working closely with Ms. Petersen and the Company's broad, experienced clinical operations team.
お知らせ • Sep 04CapsoVision, Inc. Announces Step Down of Kevin Lundquist as Chief Financial Officer, Effective August 27, 2025Effective August 27, 2025, Kevin Lundquist has stepped down as Chief Financial Officer of CapsoVision, Inc. (the “Company”). The Company has begun the search to identify a successor. The Company and Mr. Lundquist have mutually agreed that Mr. Lundquist will be available to provide consulting assistance and transition support to the Company for up to six months, until February 28, 2026. In connection therewith, the Company and Mr. Lundquist will enter into a Consulting Agreement to take effect immediately (the “ Consulting Agreement ”).
Reported Earnings • Aug 19Second quarter 2025 earnings: EPS and revenues exceed analyst expectationsSecond quarter 2025 results: US$2.02 loss per share. Net loss: US$4.63m (flat on 2Q 2024). Revenue exceeded analyst estimates by 2.1%. Earnings per share (EPS) also surpassed analyst estimates by 10%. Revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 8.2% growth forecast for the Medical Equipment industry in the US.
お知らせ • Aug 01CapsoVision, Inc. to Report Q2, 2025 Results on Aug 14, 2025CapsoVision, Inc. announced that they will report Q2, 2025 results After-Market on Aug 14, 2025
お知らせ • Jul 02CapsoVision, Inc. has completed an IPO in the amount of $27.5 million.CapsoVision, Inc. has completed an IPO in the amount of $27.5 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 5,500,000 Price\Range: $5 Discount Per Security: $0.35 Transaction Features: Sponsor Backed Offering
Board Change • Jun 30Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Independent Chairman Chen Tsai was the last independent director to join the board, commencing their role in 2014. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
